GLP-1 Agonist
    Prescription Required

    Tirzepatide (GIP/GLP-1)

    Dual-Action Weight Loss Powerhouse

    A dual GIP and GLP-1 receptor agonist showing even greater weight loss than semaglutide, representing the next generation of metabolic therapies.

    Superior weight lossEnhanced metabolic healthBlood sugar optimizationAppetite controlPotential muscle preservation

    About Tirzepatide (GIP/GLP-1)

    Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity) is a first-in-class dual GIP and GLP-1 receptor agonist. By targeting two incretin pathways instead of one, tirzepatide has demonstrated weight loss results that surpass semaglutide—with some participants losing over 20% of body weight. This dual mechanism may also provide better muscle preservation during weight loss compared to GLP-1 alone. Tirzepatide represents the cutting edge of metabolic medicine and has been called a 'game-changer' in obesity treatment.

    Mechanism of Action

    Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. While GLP-1 slows gastric emptying and reduces appetite, GIP appears to enhance fat burning and may help preserve lean mass. Together, these pathways create synergistic effects on appetite, blood sugar, and body composition that exceed what either pathway achieves alone.

    How Tirzepatide (GIP/GLP-1) Works in Your Body:

    • Target Receptors: Tirzepatide (GIP/GLP-1) binds to specific receptors that trigger downstream signaling cascades related to its primary benefits.
    • Physiological Response: The body responds by modulating natural processes—whether hormone release, tissue repair, or cellular signaling—without replacing endogenous function.
    • Timeline: Effects typically begin within a few days, with optimal results seen over the recommended protocol duration.

    Dosing Protocol

    Frequency

    Once weekly (injectable)

    Timing

    Same day each week, any time of day

    Duration

    Long-term under medical supervision

    Important Notes

    Start at 2.5mg weekly and titrate up every 4 weeks. Maximum dose 15mg weekly. Can be taken with or without food.

    Clinical Research

    4 studies on Tirzepatide (GIP/GLP-1)

    Study #01

    SURMOUNT-1 Trial

    Participants on highest dose lost an average of 22.5% body weight—more than any previous medication.

    New England Journal of Medicine

    Study #02

    SURPASS Trials

    Tirzepatide showed superior HbA1c reduction compared to semaglutide and all other comparators.

    The Lancet

    Study #03

    Body Composition Analysis

    Tirzepatide demonstrated favorable effects on lean mass preservation compared to caloric restriction alone.

    Nature Medicine

    Study #04

    Cardiovascular Outcomes

    SURPASS-CVOT trial ongoing to assess long-term cardiovascular benefits.

    Circulation

    Potential Side Effects

    • Nausea (common, usually temporary)
    • Diarrhea
    • Decreased appetite
    • Injection site reactions
    • Rare: pancreatitis risk

    Stacks Well With

    Combining peptides can create synergistic effects. Learn about optimal timing, dosing, and protocols.

    Learn More About Tirzepatide (GIP/GLP-1)

    Explore our research library and educational resources to understand how Tirzepatide (GIP/GLP-1) can support your health goals.